Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790582 · ClinicalTrials.gov registry record · Phase 2
A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Forbes Norris MDA/ALS Research Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
- 10
- Study locations
NCT00790582: Completed Phase 2 study of Amyotrophic Lateral Sclerosis, sponsored by Forbes Norris MDA/ALS Research Center.
NCT00790582 is a Phase 2 study of Amyotrophic Lateral Sclerosis that has completed, run by Forbes Norris MDA/ALS Research Center. The registered enrollment target is 109 participants, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (88% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00790582, a Phase 2 study of Amyotrophic Lateral Sclerosis, has completed, sponsored by Forbes Norris MDA/ALS Research Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a Phase II screening study of lithium carbonate in ALS. The purpose of this study is to find out if lithium carbonate is safe to be used in people with ALS and if it can slow the progression of the disease. Since there is no placebo in this study, all patients will be taking lithium carbonate.
Primary Outcome
This questionnaire has 12 questions about the patient's ability to complete certain daily activities. There are three questions each about the mouth area, arms, legs, and breathing. A normal score is 48 with each question scored at 0 (worst) to 4 (normal function). In research studies, the change in slope is measured in number of points changed per month. Maximum possible=48 (normal) Minimum=0 (severe dysfunction)
Conditions Studied
Interventions
- DRUG lithium carbonate
Study Locations (10)
California
- UCLA Neuromuscular Research Center - Los Angeles
- UC Irvine MDA/ALS & Neuromuscular Center - Orange
- California Pacific Medical Center - San Francisco
Arizona
- Mayo Clinic - Scottsdale
Kansas
- Kansas University Medical Center - Kansas City
Missouri
- Washington University Department of Neurology - St Louis
Oregon
- Providence ALS Clinic - Portland
Pennsylvania
- University of Pennsylvania Neurological Institute - Philadelphia
Texas
- Methodist Neurological Institute - Houston
Utah
- University of Utah Clinical Neurosciences Center - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
What the finished NCT00790582 record still lists
NCT00790582 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, below the 897-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which lithium carbonate is the first listed.
NCT00790582 lists 10 locations in 8 states (California, Arizona, Kansas).
Frequently Asked Questions
What is clinical trial NCT00790582 about?
NCT00790582 is a clinical study titled "A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)". This is a Phase II screening study of lithium carbonate in ALS. The purpose of this study is to find out if lithium carbonate is safe to be used in people with ALS and if it can slow the progression of the disease. Since there is no placebo in this study, all patients will be taking lithium carbonat...
What is the current status of trial NCT00790582?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2008-05. Estimated completion is 2010-03.
What conditions does trial NCT00790582 study?
This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis.
What interventions are being tested in trial NCT00790582?
The interventions under investigation include: lithium carbonate (DRUG).
Who is sponsoring clinical trial NCT00790582?
This trial is sponsored by Forbes Norris MDA/ALS Research Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00790582 being conducted?
This trial has 10 study locations across Arizona, California, Kansas, Missouri, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyotrophic Lateral Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00790582's enrollment target sits among peer trials
109 38th of 102 higher than 65 of 102 other Amyotrophic Lateral Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amyotrophic Lateral Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
RECRUITING · Phase 2
-
HEALEY ALS Platform Trial - Master Protocol
RECRUITING · Phase 2
-
RAPA-501 Therapy for ALS
RECRUITING · Phase 2
-
A Study of Ranolazine in ALS
RECRUITING · Phase 2
-
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia